Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal

被引：7

作者：

Kislaya, Irina ^{[1
,2
,7
]}

Casaca, Pedro ^{[3
]}

Borges, Vitor ^{[1
]}

Sousa, Carlos ^{[4
]}

Ferreira, Bibiana I. ^{[5
]}

Fonte, Ana ^{[6
]}

Fernandes, Eugenia ^{[1
,2
,3
,4
,5
,6
]}

Dias, Carlos Matias ^{[1
,2
]}

Duarte, Silvia ^{[1
]}

Almeida, Jose Pedro ^{[4
]}

Grenho, Ines ^{[1
,2
,4
,5
,6
]}

Coelho, Luis ^{[1
]}

Ferreira, Rita ^{[1
]}

Ferreira, Patricia Pita ^{[3
]}

Borges, Claudia Medeiros ^{[1
,2
,4
,5
,6
]}

Isidro, Joana ^{[1
]}

Pinto, Miguel ^{[1
]}

Menezes, Luis ^{[4
]}

Sobral, Daniel ^{[1
]}

Nunes, Alexandra ^{[1
]}

Santos, Daniela ^{[1
]}

Goncalves, Antonio Maia ^{[4
]}

Vieira, Luis ^{[1
]}

Gomes, Joao Paulo ^{[1
]}

Leite, Pedro Pinto

Nunes, Baltazar ^{[1
,2
]}

Machado, Ausenda ^{[1
,2
]}

Peralta-Santos, Andre ^{[2
]}

机构：

[1] Inst Nacl Saude Doutor Ricardo Jorge, Lisbon, Portugal

[2] Comprehens Hlth Res Ctr, Lisbon, Portugal

[3] Direcao Geral Saude, Lisbon, Portugal

[4] Unilabs, Porto, Portugal

[5] Algarve Biomed Ctr Res Inst, Faro, Portugal

[6] Administrasao Cent Sistema Saude, Lisbon, Portugal

[7] Inst Nacl Saude Doutor Ricardo Jorge, Ave Padre Cruz, P-1649016 Lisbon, Portugal

来源：

EMERGING INFECTIOUS DISEASES | 2023年 / 29卷 / 03期

关键词：

D O I：

10.3201/eid2903.221367

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We estimated comparative primary and booster vaccine effectiveness (VE) of SARS-CoV-2 Omicron BA.5 and BA.2 lineages against infection and disease progression. During April-June 2022, we implemented a case-case and cohort study and classified lineages using whole-genome sequencing or spike gene target failure. For the case-case study, we estimated the adjusted odds ratios (aORs) of vaccination using a logistic regression. For the cohort study, we estimated VE against disease progression using a penalized logistic regression. We observed no reduced VE for primary (aOR 1.07 [95% CI 0.93-1.23]) or booster (aOR 0.96 [95% CI 0.84-1.09]) vaccination against BA.5 infection. Among BA.5 case -pa-tients, booster VE against progression to hospitalization was lower than that among BA.2 case-patients (VE 77% [95% CI 49%-90%] vs. VE 93% [95% CI 86%-97%]). Al-though booster vaccination is less effective against BA.5 than against BA.2, it offers substantial protection against progression from BA.5 infection to severe disease.

引用

页码：569 / 575

页数：7

共 50 条

[21] SARS-CoV-2 Omicron variants BA.4 and BA.5 dominated the fifth COVID-19 epidemiological wave in Mexico
Taboada, Blanca Itzelt
Zarate, Selene
Garcia-Lopez, Rodrigo
Munoz-Medina, Jose Esteban
Gomez-Gil, Bruno
Herrera-Estrella, Alfredo
Sanchez-Flores, Alejandro
Salas-Lais, Angel Gustavo
Roche, Benjamin
Martinez-Morales, Gabriela
Zarate, Hermilo Dominguez
Molina, Celida Duque
Hernandez, Ricardo Aviles
Lopez, Susana
Arias, Carlos F.
MICROBIAL GENOMICS, 2023, 9 (12):
[22] Comparative subgenomic mRNA profiles of SARS-CoV-2 Alpha, Delta and Omicron BA.1, BA.2 and BA.5 sub-lineages using Danish COVID-19 genomic surveillance data
Tang, Man-Hung Eric
Ng, Kim Lee
Edslev, Sofie Marie
Ellegaard, Kirsten
Stegger, Marc
Alexandersen, Soren
EBIOMEDICINE, 2023, 93
[23] Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study
He, Xiaofeng
Zeng, Biao
Wang, Ye
Pang, Yulian
Zhang, Meng
Hu, Ting
Liang, Yuanhao
Kang, Min
Tang, Shixing
FRONTIERS IN IMMUNOLOGY, 2023, 14
[24] Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
Tseng, Hung Fu
Ackerson, Bradley K.
Bruxvoort, Katia J.
Sy, Lina S.
Tubert, Julia E.
Lee, Gina S.
Ku, Jennifer H.
Florea, Ana
Luo, Yi
Qiu, Sijia
Choi, Soon Kyu
Takhar, Harpreet S.
Aragones, Michael
Paila, Yamuna D.
Chavers, Scott
Talarico, Carla A.
Qian, Lei
NATURE COMMUNICATIONS, 2023, 14 (01)
[25] Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
Hung Fu Tseng
Bradley K. Ackerson
Katia J. Bruxvoort
Lina S. Sy
Julia E. Tubert
Gina S. Lee
Jennifer H. Ku
Ana Florea
Yi Luo
Sijia Qiu
Soon Kyu Choi
Harpreet S. Takhar
Michael Aragones
Yamuna D. Paila
Scott Chavers
Carla A. Talarico
Lei Qian
Nature Communications, 14
[26] Estimation of mRNA COVID-19 Vaccination Effectiveness in Tokyo for Omicron Variants BA.2 and BA.5: Effect of Social Behavior
Kodera, Sachiko
Niimi, Yuki
Rashed, Essam A.
Yoshinaga, Naoki
Toyoda, Masashi
Hirata, Akimasa
VACCINES, 2022, 10 (11)
[27] Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
Spyros Chalkias
Jordan L. Whatley
Frank Eder
Brandon Essink
Shishir Khetan
Paul Bradley
Adam Brosz
Nichole McGhee
Joanne E. Tomassini
Xing Chen
Xiaoping Zhao
Andrea Sutherland
Xiaoying Shen
Bethany Girard
Darin K. Edwards
Jing Feng
Honghong Zhou
Stephen Walsh
David C. Montefiori
Lindsey R. Baden
Jacqueline M. Miller
Rituparna Das
Nature Medicine, 2023, 29 : 2325 - 2333
[28] Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
Chalkias, Spyros
Whatley, Jordan L.
Eder, Frank
Essink, Brandon
Khetan, Shishir
Bradley, Paul
Brosz, Adam
Mcghee, Nichole
Tomassini, Joanne E.
Chen, Xing
Zhao, Xiaoping
Sutherland, Andrea
Shen, Xiaoying
Girard, Bethany
Edwards, Darin K.
Feng, Jing
Zhou, Honghong
Walsh, Stephen
Montefiori, David C.
Baden, Lindsey R.
Miller, Jacqueline M.
Das, Rituparna
NATURE MEDICINE, 2023, 29 (9) : 2325 - 2333
[29] Comparison of neutralization activity against Omicron BA.2/BA.5 in sera from HCWs receiving heterologous/homologous COVID-19 vaccines
Amano, Masayuki
Ichikawa, Yasuko
Uemura, Yukari
Matsumoto, Shota
Maeda, Kenji
Matsushita, Shuzo
Shimada, Shinya
Mitsuya, Hiroaki
JOURNAL OF INFECTION, 2023, 86 (05) : E130 - E132
[30] Comparison of SARS-CoV-2 Viral Loads in the Nasal Mucosa of Patients Infected With BA.1, BA.2, or BA.5 Omicron Lineages
Tozer, Kyla
Sjaarda, Calvin P.
Moslinger, Emily
Wong, Henry
Mubareka, Samira
Maguire, Finlay
Fattouh, Ramzi
Brabant-Kirwan, Danielle
Kozak, Robert
Sheth, Prameet M.
OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (12):

← 1 2 3 4 5 →